Group 1 - The core advantage of generic drugs is the lower R&D investment required [1] - GLP-1 peptide drugs are well-known for their triple benefits: blood sugar reduction, weight loss, and cardiovascular protection, making them a highly competitive area in innovative pharmaceuticals [3] - Saintno Biological (688117.SH), a company listed on the Sci-Tech Innovation Board, focuses on providing CDMO services for innovative peptide drugs and developing raw materials and formulations for generic peptides [4][5] Group 2 - According to the third-quarter earnings forecast disclosed by Saintno Biological in mid-October, the expected net profit for the first three quarters is between 114 million to 140 million, representing a year-on-year growth of 100.53% to 145.10% [6] - The expected non-net profit for the same period is between 113 million to 138 million, with a year-on-year growth of 111.26% to 158.21% [6]